{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000050","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.783354+00:00","generated_at":"2026-06-04T04:46:01.487596+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Autolus appoints Mike Bonney as Chair and Ravi Rao as director; John Johnson resigns effective April 1, 2024","bullets":["John H. Johnson steps down as Chairman and Non-Executive Director; departure not due to disagreements.","Mike Bonney appointed Chairman of the Board; over 30 years biotech experience, formerly CEO of Cubist Pharmaceuticals.","Ravi Rao, M.D. appointed Non-Executive Director; current CMO of Sitryx and previous CMO at Oxford Biomedica.","Board changes effective April 1, 2024; Bonney and Rao receive annual retainers and initial option awards.","Press release notes recent FDA acceptance of BLA for obe-cel in r/r adult B-cell ALL as key company milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000050","json":"https://secwatch.observer/filing/0001730463-24-000050.json","markdown":"https://secwatch.observer/filing/0001730463-24-000050.md","text":"https://secwatch.observer/filing/0001730463-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/autl-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:46:01.487596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43f776e868","claim":"John Johnson resigned as Chairman of the Board at Autolus Therapeutics plc.","evidence_excerpt":"On March 26, 2024, John Johnson notified Autolus Therapeutics plc (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective April 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"9a42a7212c","claim":"Michael Bonney was appointed as Chairman of the Board at Autolus Therapeutics plc.","evidence_excerpt":"appointed Michael W. (“Mike”) Bonney to serve as a Class II director of the Company and as Chair of the Board, effective April 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"e485238ff4","claim":"Ravi Rao was appointed as Non-Executive Director at Autolus Therapeutics plc.","evidence_excerpt":"appointed Ravi M. Rao, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Non-Executive Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}